Kadmon Holdings (Kadmon Holdings) Inventory-to-Revenue : 0.00 (As of Sep. 2021)

View and export this data going back to 2016. Start your Free Trial

What is Kadmon Holdings Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Kadmon Holdings's Average Total Inventories for the quarter that ended in Sep. 2021 was $0.02 Mil. Kadmon Holdings's Revenue for the three months ended in Sep. 2021 was $14.71 Mil. Kadmon Holdings's Inventory-to-Revenue for the quarter that ended in Sep. 2021 was 0.00.

Kadmon Holdings's Inventory-to-Revenue for the quarter that ended in Sep. 2021 declined from Jun. 2021 (0.09) to Jun. 2021 (0.00)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Kadmon Holdings's Days Inventory for the three months ended in Sep. 2021 was 2.41.

Inventory Turnover measures how fast the company turns over its inventory within a year. Kadmon Holdings's Inventory Turnover for the quarter that ended in Sep. 2021 was 37.82.

Kadmon Holdings Inventory-to-Revenue Historical Data

The historical data trend for Kadmon Holdings's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadmon Holdings Inventory-to-Revenue Chart

Kadmon Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Inventory-to-Revenue

Get a 7-Day Free Trial

0.10

0.09

0.40

0.15

0.05

Kadmon Holdings Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Inventory-to-Revenue	Get a 7-Day Free Trial															0.15	0.11	0.11	0.09	-

Competitive Comparison of Kadmon Holdings's Inventory-to-Revenue

For the Biotechnology subindustry, Kadmon Holdings's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kadmon Holdings's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kadmon Holdings's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kadmon Holdings's Inventory-to-Revenue falls into.

Kadmon Holdings Inventory-to-Revenue Calculation

Kadmon Holdings's Inventory-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as

	Inventory-to-Revenue (A: Dec. 2020 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2019 )	+	Total Inventories (A: Dec. 2020 ))	/	count )	/	Revenue (A: Dec. 2020 )
=	( (0.64	+	0.102)	/	2 )	/	8.288
=	0.371					/	8.288
=	0.04

Kadmon Holdings's Inventory-to-Revenue for the quarter that ended in Sep. 2021 is calculated as

	Inventory-to-Revenue (Q: Sep. 2021 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2021 )	+	Total Inventories (Q: Sep. 2021 ))	/	count )	/	Revenue (Q: Sep. 2021 )
=	( (0.012	+	0.022)	/	2 )	/	14.706
=	0.017					/	14.706
=	0.00

Kadmon Holdings (NAS:KDMN) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Kadmon Holdings's Days Inventory for the three months ended in Sep. 2021 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2021 )	/	Cost of Goods Sold (Q: Sep. 2021 )	*	Days in Period
	=	0.017	/	0.643	*	365 / 4
	=	2.41

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Kadmon Holdings's Inventory Turnover for the quarter that ended in Sep. 2021 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2021 )	/	Average Total Inventories (Q: Sep. 2021 )
	=	0.643	/	0.017
	=	37.82

Kadmon Holdings Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kadmon Holdings's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kadmon Holdings (Kadmon Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadmon Holdings Inc (NAS:KDMN) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 East 29th Street, New York, NY, USA, 10016

Website

https://www.kadmon.com

Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.

Executives

Harlan Waksal	director, officer: President, CEO	WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David E Cohen	director	3160 PORTER DRIVE, PALO ALTO CA 94304
Eugene Bauer	director	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016
Tasos Konidaris	director	103 JFK PARKWAY, SHORT HILLS NJ 07078
John L Ryan	officer: Executive Vice President, CMO	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Steven Meehan	officer: EVP, Chief Financial Officer	450 E. 29TH STREET NEW YORK NY 10016
Kyle Carver	officer: Principal Accounting Officer, Controller	450 EAST 29TH STREET NEW YORK NY 10016
Gregory S. Moss	officer: EVP, General Counsel, Chief Compliance Officer	450 EAST 29TH STREET, 16TH FLOOR, NEW YORK NY 10016
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	other: Former 10% owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Steven N. Gordon	officer: Exec VP, GC, Chief Admin, Comp	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016